The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
- Conditions
- Chronic Kidney DiseaseHeart Failure With Preserved Ejection Fraction (HFPEF)Obesity (Disorder)
- Registration Number
- NCT07052539
- Lead Sponsor
- University of Mississippi Medical Center
- Brief Summary
This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Adults 18-75 years old
- Normal kidney function
- No heart failure
- BMI 25-30kg/m2
- Diagnosis of chronic illness
- eGFR<60mL/min/1.73m2
- Pregnancy or breast feeding
- History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- Hemoglobin levels <7mg/dL
- Acute illness or hospitalization event within 3 months
- Unable to stop NSAIDs
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Current use of nicotine or recreational drugs, chronic drinker
Criteria for Cohort 2: Obese Participants without HFpEF
Inclusion Criteria:
- Adults 18-75 years old
- eGFR >= 60 mL/min/1.73m2
- BMI > 35 kg/m2
Exclusion Criteria:
- Diagnosis of Heart Failure
- Diagnosis of chronic illness
- eGFR<60mL/min/1.73m2
- Pregnancy or breast feeding
- History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- Hemoglobin levels <7mg/dL
- Acute illness or hospitalization event within 3 months
- Unable to stop NSAIDs
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Current use of nicotine or recreational drugs, chronic drinker
Criteria for Cohort 3: HFpEF and Obese Participants
Inclusion Criteria:
- Adults 18-75 years old
- eGFR >= 60 mL/min/1.73m2
- BMI > 35 kg/m2
- Diagnosis of HFpEF (chart diagnosis, LVEF > 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6
Exclusion Criteria:
- NYHA class III/IV
- Urinary retention screen +
- Mobility issues
- History of RRT or kidney transplant
- Acute illness/hospitalization in the past 3 months
- History of cancer, chemo, or XRT
- Pregnant/breastfeeding
- History of allergies to contrast
- Hemoglobin < 7
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Unable to stop NSAIDs
- Current use of nicotine or recreational drugs, chronic drinker
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in measured GFR 5 hours Change in urine sodium excretion 5 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
University of Mississippi Medical Center🇺🇸Jackson, Mississippi, United StatesTekka JohnsonContact601-496-7834tjohnson23@umc.eduMarissa C Tio, MDPrincipal Investigator